Preliminary Feedback Reports for 2019
Log into the QPP website to access your preliminary feedback reports.
A screen will display reminding you that the data is preliminary and will be finalized later in the summer of 2020 (July). When the reports are finalized, you will be able to submit a Targeted Review if needed. You must agree to continue.
Click on Download Data to access the Submission Data that CMS received from you either through manual entry, submission by your EHR, or submission through a third-party vendor. The Connected Clinicians included in the report are also available here.
Click on View Practice Details to go to your Performance Feedback Report.
MIPS in 2020
At this time, 2020 has not been designated as a year of Extreme and Uncontrollable Circumstances (EUC) by CMS. I anticipate that this will happen, and when it does, you still need to evaluate whether it is in your best interest to apply for an exception or continue to submit data as you normally would. You may be able to do both, apply for the exception and then depending on how your data looks, go ahead and submit in the beginning of 2021. Typically, submission trumps an exception application and we will keep an eye out for this as the year unfolds and CMS issues guidance.
The payment adjustment in 2022, for the 2020 performance year, is set at +/- 9%, maintaining budget neutrality. This means positive adjustments may be lower than expected but are still positive! Here is the breakdown:
Approved EUC Application = Neutral adjustment
Final Score above 45 pts = Positive Adjustment between 0 – 9% (adjusted to remain budget neutral)
Exceptional Performer (> 85 pts) = Positive Adjustment 9% (adjusted to remain budget neutral) + a percentage of the $500 million set aside for exceptional performers
We are happy to assist you with monitoring your MIPS data and/or making decisions for your 2020 submission. Just let us know!
New Improvement Activity
Due to the Public Health Emergency, a new Improvement Activity has been added - (IA_ERP_3) COVID-19 Clinical Trials Improvement Activity.
To use this high priority measure, you must be able to attest that you are participating in a COVID-19 clinical trial utilizing a drug or biological product to treat a patient with a COVID-19 infection and report their findings through a clinical data repository or clinical data registry for the duration of their study.
Reporting of this data would also meet the requirements for one of you Public Health Measures in the Promoting Interoperability category.